Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase

Early Phase 1

Active, not recruiting

• Conditions: Drug Safety
• Interventions: Drug: Hyaluronidase

• Registration Number: NCT01722916
• Lead Sponsor: Northwestern University

Brief Summary

The purpose of this study is to find how much hyaluronidase should be used when receiving injections of fillers.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-10
• Study First Submitted: 2012-11-05
• Study First Submitted QC: 2012-11-05
• Study First Posted: 2012-11-07
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-01
• Last Update Posted: 2024-02-05
• Primary Completion: 2024-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

• Age 18 and over
• The subjects are in good health
• The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator

Read More

Exclusion Criteria

• Under 18 years of age
• Pregnancy or Lactation
• Subjects who are unable to understand the protocol or to give informed consent
• Subjects with mental illness
• Recent Accutane use in the past 6 months
• Subjects prone to hypertrophic and keloidal scarring
• Subjects with tattoos and/or scars on upper medial arms (the treatment area)
• Subjects with known hypersensitivity to hyaluronic acid

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dose of Hyaluronidase	Hyaluronidase	-

Primary Outcome Measures

Name	Time	Method
Dose of hyaluronidase injected until the filler is no longer detectable	2 weeks

Trial Locations

Locations (1)

Northwestern University Department of Dermatology; 🇺🇸 Chicago, Illinois, United States